Fuller & Thaler Asset Management Inc. Reduces Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Fuller & Thaler Asset Management Inc. trimmed its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 0.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,932,279 shares of the life sciences company's stock after selling 35,283 shares during the period. Fuller & Thaler Asset Management Inc. owned approximately 5.10% of Integra LifeSciences worth $89,184,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank bought a new position in Integra LifeSciences in the fourth quarter valued at $8,967,000. Access Investment Management LLC purchased a new position in shares of Integra LifeSciences in the 4th quarter worth about $4,416,000. Cannell & Spears LLC bought a new position in shares of Integra LifeSciences during the 4th quarter valued at about $3,555,000. First Trust Advisors LP raised its holdings in shares of Integra LifeSciences by 319.7% during the 4th quarter. First Trust Advisors LP now owns 186,300 shares of the life sciences company's stock valued at $4,225,000 after buying an additional 141,907 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Integra LifeSciences by 130.5% in the 4th quarter. JPMorgan Chase & Co. now owns 199,691 shares of the life sciences company's stock worth $4,529,000 after buying an additional 113,061 shares during the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Trading Down 1.5 %

NASDAQ:IART traded down $0.25 during midday trading on Monday, reaching $16.56. 241,333 shares of the stock traded hands, compared to its average volume of 1,035,282. The stock has a market capitalization of $1.28 billion, a P/E ratio of -184.09, a PEG ratio of 0.73 and a beta of 1.24. Integra LifeSciences Holdings Co. has a 12 month low of $14.45 and a 12 month high of $32.66. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The company has a fifty day moving average of $20.51 and a 200 day moving average of $22.23.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $442.65 million during the quarter, compared to the consensus estimate of $445.15 million. During the same period in the prior year, the firm posted $0.89 earnings per share. The company's quarterly revenue was up 11.5% compared to the same quarter last year. On average, research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on IART shares. Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Truist Financial decreased their target price on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $22.71.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.